Vivos Therapeutics, INC

Vivos Therapeutics, Inc. announces the departure of its CFO, Bradford Amman, and the appointment of Roman Franklin as interim CFO through a services agreement with The CFO Portal, LLC.

Vivos Therapeutics, Inc. announced the closing of a $2.1 million private placement, issuing units of preferred stock and warrants to V-Co Investors 4 LLC and Bigger Capital Fund, LP.

Vivos Therapeutics has extended the deadline for its $4.5 million debt-to-equity conversion agreement with Streeterville Capital to August 31, 2026.

Vivos Therapeutics plans to raise capital through a proposed rights offering of transferable subscription rights to shareholders.

Vivos Therapeutics announces a binding agreement to exchange up to $4.5 million in debt for equity with Streeterville Capital, aiming to improve stockholder equity and address Nasdaq listing requirements, while also securing a new $5 million convertible note from V-Co Investors 4 LLC.

Vivos Therapeutics has been notified by Nasdaq that it fails to meet the minimum stockholders' equity requirement for continued listing.

Vivos Therapeutics reports Q1 2026 revenue of $5.1 million, driven by its new medical-provider focused business model, while facing ongoing liquidity and Nasdaq compliance challenges.

Vivos Therapeutics, Inc. reported a significant increase in net losses and a going concern warning despite revenue growth driven by its new acquisition-focused business model.

Vivos Therapeutics, Inc. reported increased net losses and a significant cash burn for the first half of 2025, despite a strategic pivot towards acquiring and managing sleep treatment centers.

Vivos Therapeutics' Q1 2025 revenue decreased by 12% year-over-year as the company transitions its business model towards strategic alliances and acquisitions of sleep centers.

Vivos Therapeutics saw a revenue increase in Q3 2024, driven by product sales and a strategic shift towards alliances with sleep centers.

Vivos Therapeutics, Inc. reports a $7.5 million private placement and a strategic shift towards alliances with sleep centers, alongside its Q2 2024 financial results.

Vivos Therapeutics, Inc. announced its fiscal year 2025 results, showing a 16% increase in total revenue to $17.4 million, driven by growth in sleep testing services and treatment revenue, despite a decline in product sales.

Vivos Therapeutics pivots towards strategic alliances and acquisitions to drive revenue growth after mixed results in 2024.

Vivos Therapeutics has filed an amendment to its 2023 annual report to correct a minor typographical error, while reaffirming the accuracy of its financial statements.

Vivos Therapeutics reports a net loss of $13.6 million for 2023, while implementing strategic changes and navigating market headwinds.

Michael C Skaff, a 10% owner of Vivos Therapeutics, Inc., purchased 5,498,660 shares of common stock on June 30, 2026 for $0.58 per share.

Michael C. Skaff, a Director at Vivos Therapeutics, Inc., reported transactions involving the conversion of a promissory note and the acquisition of warrants, increasing his indirect beneficial ownership.

Vivos Therapeutics CEO Ronald Kirk Huntsman acquired 315,421 stock options and disposed of 3,461 common shares, while also holding 69,600 shares indirectly.

Vivos Therapeutics' Chief Financial Officer, Bradford K. Amman, acquired 149,533 stock options after shareholder approval of the 2024 Omnibus Equity Incentive Plan.

Ronald Kirk Huntsman, CEO of Vivos Therapeutics, reports the acquisition of 20,000 stock options and a disposition of 3,461 shares of common stock.

Director Leonard J. Sokolow of Vivos Therapeutics, Inc. received a grant of 4,000 stock options on June 20, 2024.

Vivos Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on November 4, 2025, seeking approval for director elections, an increased equity incentive plan, and auditor ratification.

Vivos Therapeutics urges stockholders to vote in favor of proposals at the upcoming annual meeting after a year of regulatory approvals, revenue enhancement efforts, and balance sheet improvements.

Vivos Therapeutics is asking stockholders to approve the 2024 Omnibus Equity Incentive Plan at the upcoming annual meeting on November 26, 2024.

Vivos Therapeutics has filed an amendment to its S-1 registration statement, primarily to remove reliance on previously incorporated information, relating to the potential resale of common stock and warrants.

Vivos Therapeutics is registering for resale 854,332 shares of common stock, including shares underlying warrants issued in recent private placements.

Vivos Therapeutics has filed an amendment to its Form S-1 registration statement to allow for the resale of up to 1,737,259 shares of common stock underlying warrants held by a selling stockholder.

Vivos Therapeutics has filed a registration statement for the resale of up to 1,737,259 shares of common stock by a selling stockholder, derived from warrants issued in private placements.

A group of investment entities and their manager have disclosed a significant beneficial ownership stake in Vivos Therapeutics, Inc., totaling 19.9% as of July 15, 2026.

Vivos Therapeutics, Inc. (VVOS) has filed a Schedule 13D detailing significant shareholdings and a recent private placement involving V-CO Investors LLC and its affiliates.

A group of investors led by SP Manager LLC and Michael C. Skaff has acquired a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. through a private placement, providing capital for the company's acquisition of The Sleep Center of Nevada and general working capital.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 8.27% of Vivos Therapeutics, Inc. common stock as of March 31, 2026.

Dawei Luo has filed a Schedule 13G, revealing a passive beneficial ownership of 8.52% of Vivos Therapeutics Inc.'s common stock, totaling 572,016 shares.